A Biologics Series 

Bactericidal Antibody Response: Measuring Immunogenicity and Vaccine Efficacy

Presented by Nexelis

Thursday 23 June 2022 at 14:00 |


Full Details

Infectious diseases originate from both viruses and bacteria.  When designing a prophylactic vaccine for bacteria based upon the structure.  In our example, Neisseria meningitidis both the structure and the serogroup must be considered.

During the webinar, our scientists highlight assay development to measure and quantify the efficacy of bacterial prophylactic vaccines.  Utilizing Neisseria meningitidis as an example, we feature the key components of designing an assay and scaling to support clinical studies.  From the laboratory perspective, we share our knowledge of not only the bacteria but also the signaling pathway, which is fundamental when executing a functional assay.

It is critical that our team of scientists have the depth of knowledge in both the infectious disease and the technique by which to measure the neutralization of the bacteria.  This is necessary to avoid misrepresentation of data or calculations when measuring the titer to determine vaccine efficacy.

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.

Member Community Login

Thank you for your query

A member of our team will be in touch soon